DailyIQ
Last updatedjust now

DHR·Danaher Corporation

$224.90
+2.06 (+0.92%)
High
$227.86
Open
$225.00
Market Cap
157.03B
52W High
$244.32
Low
$222.74
P. Close
$224.90
P/E
39.22
52W Low
$160.93
Fwd P/E
23.97
DailyIQ Est.
$253.71
Inst. Ownership
39.3%
Short Interest
1.28%
Days to Cover
1.8
Div. Yield
0.68%
Next Ex-Div
~Dec 30
Div. Growth
12+ yrs
NewEarnings release, scored · filed Jul 20, 2026Guidance raised · tone -0.3 vs prior release · 43 lines scoredSee the breakdown
Technical Score (1D)
37
BEARISH
News Sentiment
66
BULLISH
On Oct 13, TD Cowen increased its price target for Danaher (DHR) from $236 to $255, indicating a more optimistic view of the company’s earnings prospects. The upgrade reflected confidence in Danaher’s growth trajectory and its ability to generate higher cash flows. TD Cowen did not provide detailed justification for the specific level of the new target. The move was reported to signal a potential upside for investors, though the firm’s explanation remained sparse. The adjustment was noted as a possible influence on market sentiment and DHR’s valuation.
LOW TARGET
$200 -11.1%
2 analysts
MEAN TARGET
$242 +7.6%
10 analysts
HIGH TARGET
$310 +37.8%
22 analysts
PRICE RANGE
$200.00 - $310.00
SB / B / H / S / SS
12/15/5/1/1
DAILYIQ EST.
$253.71 (+12.8%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Symbol
DHR
Description
Danaher Corporation is a global manufacturer and marketer of diverse products and services, primarily catering to the professional, medical, and industrial sectors. The company operates through three key segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment focuses on bioprocessing technologies and consumables, supporting the development and manufacturing of therapeutics. The Life Sciences segment supplies instruments, consumables, and services for a wide range of applications, including genomics, proteomics, and microscopy. Finally, the Diagnostics segment provides clinical instruments, software, and consumables utilized in clinical chemistry, immunoassay, and hematology for various healthcare settings. Founded in 1969 and headquartered in Washington, D.C., Danaher Corporation has evolved from its origins to become a significant player in the scientific and medical industries.
Bought (1Y)
0 shares
$0
Sold (1Y)
60,958 shares
$13.3M
Blair RainerPresident & CEO
Sell7,755 shares2026-08-21
Blair RainerPresident & CEO
Sell39,193 shares2026-08-21
Blair RainerPresident & CEO
Sell11,307 shares2026-08-21
RALES STEVEN MChairman
Award/Grant1,000,000 shares2026-08-04
RALES STEVEN MChairman
Award/Grant500,000 shares2026-08-04
74/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
59.1%
Net Margin
14.7%
Revenue CAGR
4.6%
Current Ratio
1.87x
Debt / Equity
0.35x
Return on Equity
6.9%
Earnings Summary
Danaher Corporation is a global manufacturer and marketer of products and services across biotechnology, life sciences, and diagnostics, operating in the healthcare sector with a focus on professional, medical, and industrial markets. The company’s recent earnings show a mixed performance: revenue increased from $6.538 billion in Q4 2024 to $6.854 billion in Q1 2025, then to $6.936 billion in Q2 2025, and $6.053 billion in Q1 2026, indicating a revenue dip in the latest quarter. EPS rose from $2.14 in Q4 2024 to $1.88 in Q1 2025, then to $1.80 in Q2 2025, and $2.06 in Q1 2026, showing a rebound in earnings per share after a dip in Q2 2025. Danaher has consistently beat EPS estimates in the last four quarters, with actual EPS exceeding guidance in Q1 2025, Q2 2025, Q3 2025, and Q1 2026, while revenue growth has been modest but steady, with a slight decline in Q1 2026 relative to Q4 2025. Historically, Danaher has maintained a trajectory of steady revenue growth and EPS beats, with a pattern of robust product pipeline contributions and operational efficiencies. Recent news from TD Cowen on October 13 raised Danaher’s price target to $255, reflecting confidence in its earnings prospects, while Baird and Evercore lifted targets and highlighted the launch of an AI‑powered autonomous laboratory at Abcam, expected to accelerate reagent development.

EPS

EstBeatMiss
$1.56$1.75$1.94$2.13$2.32Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.92 - -
Q2'26$2.06$1.94-5.8%
Q1'26$1.86$2.06+11.0%
Q4'25$2.17$2.23+2.6%
Q3'25$1.72$1.89+9.8%
Q2'25$1.64$1.80+9.5%

Revenue

EstBeatMiss
$5.8B$6.1B$6.4B$6.7B$7.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$6.6B - -
Q2'26$6.2B$6.3B+1.7%
Q1'26$6.1B$6.0B-2.9%
Q4'25$6.9B$6.8B-0.5%
Q3'25 - $6.1B -
Q2'25 - $5.9B -

Market Data

DHR Stock Snapshot

NEUTRAL37/100
$224.90+$2.06 (0.9%)
Market cap
157.03B
P/E ratio
39.2
Day range
$222.74 – $227.86
News sentiment
66/100 · Bullish
Analyst target
$241.91 (+7.6%)
Consensus
Buy · 34 analysts
52-week range+39.8% off low · -7.9% from high
$160.93$244.32
Price $224.90 DailyIQ Est. $253.71

Neither side has the upper hand on DHR right now, and its momentum ranks near the middle of DailyIQ's universe. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into DHR?

RICH

At today's price, Danaher Corporation needs to grow free cash flow about 18.6% a year for the next 10 years to justify its valuation at a 8.54% cost of capital. Over its actual history it has compounded free cash flow at 8.4% a year, so the market is asking for 10.1 percentage points above its own delivered rate. On that basis DHR looks priced above what its own growth record supports.

Implied FCF growth
18.6%
Historical FCF CAGR
8.4%
Growth gap
+10.1 pts
Verdict
RICH
Discount rate (WACC)
8.54%
Beta
0.83

Behaviour On Record

What DHR's own history says about today's numbers

Realized volatility (21d)
29.0% 80th pct
Below its peak
-24.0%
vs 200-day average
+11.2%
Up days (1y)
51%

Danaher Corporation is currently running 29.0% annualised volatility over the last 21 sessions. Measured against DHR's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 20.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

DHR is trading -24.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -14.0%, and the deepest was -30.9% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +11.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 77th percentile — a somewhat wider gap than its own norm. Over the past year DHR closed higher on 51% of sessions, and it is currently 4 sessions into a rising streak.

On October specifically: over 14 years of records, DHR finished the month higher 9 of 14 times, with a median return of +2.3% and an average of +0.5%. Its strongest month historically has been July at +4.7% on average, its weakest February at -0.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: DHR has opened more than 2% away from the prior close in 74 of 3,268 sessions (2.3% of the time), with the largest gaps running +14.7% and -7.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, DHR moved an average of 2.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.8% and a largest of -5.6%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against DHR's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of DHR's sector?

Danaher Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for DHR?

CallsPuts

For Danaher Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.82), with at-the-money implied volatility around 39.5%. The options market is pricing roughly a ±2.6% move by that expiry — a range of about $218.32–$229.96.

Put/call ratio (2026-10-16)
0.82
ATM implied volatility
39.5%
Total open interest
13,611
Expected move by 2026-10-16
±2.6% ($218.32–$229.96)

Analyst Rating Changes

Are analysts turning bullish or bearish on DHR?

Morgan Stanley most recently reiterated its rating on Danaher Corporation to Overweight on Oct 13, 2026 with a price target of $240 (from $220). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Morgan Stanley — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 13, 2026Morgan StanleyMaintainedOverweight$220 → $240
Oct 13, 2026TD CowenMaintainedBuy$236 → $255
Oct 7, 2026BarclaysMaintainedOverweight$230 → $255
Oct 5, 2026RBC CapitalMaintainedOutperform$215 → $250
Oct 1, 2026GuggenheimMaintainedBuy$200 → $250
Jul 22, 2026Wells FargoMaintainedEqual-Weight$212 → $195
Jul 22, 2026TD CowenMaintainedBuy$240 → $236
Jul 22, 2026StifelMaintainedBuy$260 → $220
Jul 22, 2026GuggenheimMaintainedBuy$235 → $200
Jul 22, 2026RBC CapitalMaintainedOutperform$200 → $215
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$232 → $230
Jun 11, 2026Piper SandlerInitiatedNeutral$200

Earnings Release, Scored

What did Danaher Corporation's latest earnings release say?

Filed Jul 20, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone70.7/ 100-0.3 vs prior release
Hedging words0.81per 100 words-0.08 vs prior release
Tone, last 2 releasesScale 50–76

Most important lines

  1. 1

    Strong Q2 earnings performance and earlier-than-anticipated completion of Masimo acquisition enabling increased full year 2026 adjusted diluted net earnings per common share guidance.

    Guidance raised
  2. 2

    Mr. Blair continued, “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.

    New this quarter
  3. 3

    Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.

    New this quarter

Peers & ETF holders

DHR peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

66/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Danaher Corporation announced a partnership with NVIDIA to integrate AI technologies into its scientific instruments and laboratory workflows. The collaboration aims to create a continuous learning cycle where experimental data informs AI models and vice versa, speeding up scientific discovery. Danaher’s CEO highlighted the initiative as a step toward more connected, adaptive, and accessible innovation in research. The deal positions Danaher at the forefront of AI‑enabled science, potentially expanding its market influence.
What did this article say?
TD Cowen increased its price target for Danaher (DHR) from $236 to $255, reflecting a more optimistic view of the company’s earnings prospects. The upgrade signals confidence in Danaher’s growth trajectory and its ability to generate higher cash flows. The new target suggests a potential upside for investors, though the firm did not provide detailed justification for the specific level. This move may influence market sentiment and could impact DHR’s valuation in the near term.
What did this article say?
Danaher Corporation announced on October 12 that Daniel Comas and Robert Hershberg would join its Board of Directors. The appointments were made to strengthen the company’s governance and bring additional industry expertise. No immediate operational or financial implications were disclosed, and the move is considered routine corporate governance activity.
What did this article say?
In early October 2026, Danaher announced the opening of its first AI‑powered autonomous laboratory at Abcam. The facility integrates artificial intelligence, robotics, and connected workflows to accelerate the design, construction, and testing of custom antibodies and other molecular tools. A closed‑loop system feeds experimental results back into the AI models, aiming to increase both speed and scale while maintaining rigorous validation. The launch signals Danaher’s commitment to leveraging AI to enhance its reagent discovery capabilities and could position the company as a more innovative player in the life‑science tools market.
What did this article say?
Danaher’s recent launch of an AI‑powered autonomous lab at Abcam and the integration of Masimo and StatLab into its diagnostics and life sciences platforms were highlighted as potential catalysts for faster revenue conversion and future investment needs. Analysts reviewed the company’s 38.3x P/E ratio and a discounted cash flow model to assess whether the current share price aligns with projected cash flows. The review concluded that, despite the new technology initiatives, the stock remains roughly 4% undervalued relative to its valuation metrics. The analysis emphasized that the valuation gap is modest and may close as the AI lab matures. No immediate guidance changes or material events were reported.
What did this article say?
Danaher announced plans to establish an autonomous laboratory at Abcam, leveraging artificial intelligence to speed up antibody and molecular tool development. The move follows a recent rebound in the company’s share price, with a 90‑day return of 11.49% amid a broader recovery trend. Analysts view the AI lab as a strategic investment that could enhance productivity and position Danaher competitively in the life‑science sector. The announcement is expected to support future growth prospects and potentially improve valuation metrics.
What did this article say?
Danaher announced the launch of its first AI‑powered autonomous laboratory designed to speed life‑science research. The facility combines artificial intelligence, robotics, and proprietary technologies to automate complex experimental workflows, targeting faster development of custom antibodies and other research tools. By integrating this advanced lab infrastructure, Danaher expands its product portfolio and strengthens its position in the biomedical and industrial research markets.
What did this article say?
Baird increased its price target for Danaher (DHR) from $238 to $246, reflecting a more optimistic view of the company’s earnings potential. The rating remains a buy, with analysts citing steady revenue growth and a robust product pipeline. The adjustment signals confidence in DHR’s ability to maintain its competitive edge in the life‑science sector.
What did this article say?
Evercore ISI increased its price target for Danaher (DHR) from $205 to $240, reflecting a more optimistic view of the company’s earnings prospects. The rating remains a buy, with the new target suggesting a potential upside of roughly 17% over the current share price. The upgrade signals confidence in Danaher’s operational performance and growth trajectory, which may influence market sentiment and trading activity.
What did this article say?
Danaher announced the launch of an AI‑powered autonomous laboratory located at its Abcam facility, slated to begin large‑scale operations in early 2027. The new lab is designed to reduce the time from concept to validated reagent by up to eightfold, potentially accelerating the development of new therapeutics. By integrating advanced automation and machine learning, the facility aims to streamline early‑stage research and lower costs for both internal and external partners. The initiative signals Danaher’s commitment to leveraging technology to enhance its life‑science portfolio and could position the company as a leader in high‑throughput drug discovery. The move is expected to generate incremental revenue and strengthen Danaher’s competitive edge in the biotech sector.

Technical Analysis

Real-time indicators across multiple timeframes

37
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $53.45B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy60,978,3608.70%$13.96B2026-01-29
BlackRock, Inc.▲ Buy55,084,6307.86%$10.49B2026-08-07
FMR LLC (Fidelity)▲ Buy29,540,8954.21%$5.63B2026-08-13
Wellington Management Group LLP▲ Buy16,316,8342.33%$3.11B2026-08-14
Geode Capital Management, LLC▲ Buy14,280,3352.04%$2.71B2026-08-12
JPMorgan Chase & Co▼ Sell12,185,4001.74%$2.35B2026-08-12
Morgan Stanley▲ Buy11,348,9581.62%$2.16B2026-08-13
Capital Research Global Investors▲ Buy10,818,0301.54%$2.06B2026-08-12
Norges Bank▲ Buy9,537,9061.36%$1.82B2026-08-12
Northern Trust Corp▼ Sell6,925,4410.99%$1.32B2026-08-13
Janus Henderson Group plc▼ Sell6,489,9650.93%$1.22B2026-05-18
Goldman Sachs Group Inc▲ Buy5,364,8610.77%$1.02B2026-08-14
Bank of America Corp▼ Sell5,217,5860.74%$993.85M2026-08-14
Fisher Asset Management, LLC▼ Sell4,484,7740.64%$854.26M2026-08-04
Invesco Ltd.▼ Sell3,955,9920.56%$753.54M2026-08-14
AQR Capital Management LLC▼ Sell2,641,7460.38%$503.20M2026-08-14
D1 Capital Partners L.P.▼ Sell2,282,0390.33%$434.68M2026-08-14
Millennium Management LLC▲ Buy2,140,5870.31%$407.74M2026-08-14
Wells Fargo & Company▲ Buy2,107,4820.30%$401.43M2026-08-14
Neuberger Berman Group LLC▼ Sell1,853,1980.26%$353.10M2026-08-13
Glenview Capital Management, LLC▲ Buy1,145,9790.16%$218.29M2026-08-14
Prudential Financial Inc▲ Buy1,121,6400.16%$213.65M2026-08-12
Citadel Advisors LLC▼ Sell943,6940.13%$179.75M2026-09-02
Citigroup Inc▲ Buy778,2980.11%$148.25M2026-08-03
Renaissance Technologies LLC▲ Buy760,6360.11%$144.89M2026-08-13
Q2 2026 flow:18.20M sh bought ($3.47B)7.93M sh sold ($1.52B)net +10.26M sh (+$1.94B)
Congressional Trading Activity
25 disclosed trades · ~$389.5K est. traded value · 9 buys, 16 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$1K - $15K2026-09-022026-09-25
Kevin HernHouseOK01▼ Sell$15K - $50K2026-08-312026-09-25
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-10-072025-11-14
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-09-252025-10-22
Thomas H. KeanHouseNJ07▲ Buy$1K - $15K2025-09-032025-10-14
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2025-08-282025-09-03
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Pete SessionsHouseTX17▼ Sell$50K - $100K2025-06-122025-06-21
Thomas H. KeanHouseNJ07▲ Buy$1K - $15K2025-06-112025-07-16
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-04-282026-01-13
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-04-212025-05-12
Dan NewhouseHouseWA04▼ Sell$1K - $15K2025-04-112025-05-16
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-04-082025-05-08
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08
Greg LandsmanHouseOH01▼ Sell$1K - $15K2025-03-272025-04-08
Bruce WestermanHouseAR04▲ Buy$1K - $15K2025-03-042025-04-16
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-02-262025-03-06
Rob BresnahanHousePA08▼ Sell$15K - $50K2025-02-252025-03-27
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-01-152025-02-12
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12